Effect of terazosin on clinical benign prostatic hyperplasia in older adults

Journal of the American Geriatrics Society

Volumn 51, Issue 3, 2003, Pages 424-426

  Mudiyala, Radhika ^a,c   Ahmed, Ali ^a,b,c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TERAZOSIN;

ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFECT; HUMAN; MATHEMATICAL COMPUTING; META ANALYSIS; NOTE; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; TITRIMETRY; TRANSRECTAL ULTRASONOGRAPHY; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; URINARY BLADDER NECK OBSTRUCTION;

EID: 0037347577     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2003.51120.x     Document Type: Note

References (20)

1. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: Current clinical experience. Urology 2001;58:49-54.
2. O'Leary MP. Quality of life and alpha-blocker therapy: An important consideration for both the patient and the physician. Urology 2002;59:7-11.
3. Kirby RS. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology 2000;56:3-6.
4. Elhilali MM, Ramsey EW, Barkin J et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996;47:335-342.
5. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996;47:159-168.
6. Kyprianou N, Litvak JP, Borkowski A et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1810-1815.
7. Dutkiewics S. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 2001;32:423-432.
8. Roehrborn CG. Alfuzosin: Overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology 2001;58:55-63.
9. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-539.
10. Shakir S, Pearce G, Mann RD. Finasteride and tamsulosin used in benign prostatic hypertrophy: A review of the prescription-event monitoring data. BJU Int 2001;87:789-796.
11. Ramsey EW. Benign prostatic hyperplasia: A review. Can J Urol 2000;7: 1135-1143.
12. Meigs JB, Mohr B, Barry MJ et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-944.
13. Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-1474.
14. Lepor H, Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: The United States experience. Br J Urol 1992;70(Suppl. 1):2-9.
15. de La Rosette JJ, van Der Schoot DK, Debruyne FM. Recent developments in guidelines on benign prostatic hyperplasia. Curr Opin Urol 2002;12:3-6.
16. Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ 2001;323: 1042-1046.
17. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557.
18. Brawer MK, Adams G, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 1993;2:929-935.
19. Lloyd SN, Buckley JF, Chilton CP et al. Terazosin in the treatment of benign prostatic hyperplasia: A multicentre, placebo-controlled trial. Br J Urol 1992; 70(Suppl. 1):17-21.
20. Farmer A. 10-minute consultation: Prostatic symptoms. BMJ 2001;322:1468.